Cover Image
Market Research Report

Perfusion Systems Market (Cardiopulmonary Perfusion, by Component (Heart-lung Machines, Oxygenators), Ex Vivo Organ Perfusion, Technique (Hypothermic, Normothermic), Cell Perfusion, by Type (Bioreactor, Microfluidic)) - Global Forecast to 2021

Published by MarketsandMarkets Product code 494467
Published Content info 154 Pages
Delivery time: 1-2 business days
Price
Back to Top
Perfusion Systems Market (Cardiopulmonary Perfusion, by Component (Heart-lung Machines, Oxygenators), Ex Vivo Organ Perfusion, Technique (Hypothermic, Normothermic), Cell Perfusion, by Type (Bioreactor, Microfluidic)) - Global Forecast to 2021
Published: April 24, 2017 Content info: 154 Pages
Description

The perfusion systems market is projected to reach USD 1,198.8 million by 2021, at a CAGR of 3.9% during the forecast period 2016-2021. The growth of the market can be attributed to the increasing prevalence of cardiovascular and respiratory diseases, initiatives by governments and NGOs to encourage organ donation, increasing investment in cell-based research, and developments in biologics manufacturing.

The perfusion systems market is segmented on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion systems, and cell perfusion systems) and region. The global cardiopulmonary perfusion systems market is segmented based on components into oxygenators, heart-lung machines, perfusion pumps, cannulas, monitoring systems, and other components. While the oxygenators segment held the largest share of the global cardiopulmonary perfusion systems market in 2016, it is the perfusion pumps segment that is projected to grow at the highest CAGR during the forecast period.

The global cell perfusion systems market is segmented based on the type, as bioreactor perfusion systems, microfluidic perfusion systems, gravity or pressure-driven perfusion systems, and small-mammal organ perfusion systems. The bioreactor perfusion systems segment held the largest share of the market in 2016 and is also projected to register highest CAGR during the forecast period.

Based on technique, the ex vivo organ perfusion systems market is segmented into hypothermic machine perfusion and normothermic machine perfusion. The hypothermic machine perfusion segment accounted for the largest share of the market in 2016 and is also projected to grow at the highest CAGR during the forecast period.

On the basis of region, the global perfusion systems market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America held the largest share of the global market in 2016, followed by Europe.

The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, mainly due to the increasing aging population, rising organ donations and transplants in Japan, growth of the pharmaceutical and biotechnology R&D industry and CROs in China, and growing pharmaceutical & biotechnology industry and government initiatives in India.

Research Coverage:

The report studies factors affecting the growth of the perfusion systems market and analyzes opportunities and challenges in the market for stakeholders. It provides details of the competitive landscape of market leaders and analyzes micro-markets on their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market and help them garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned strategies to strengthen their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the perfusion systems market
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the perfusion systems market
  • Market Development: Information about lucrative emerging markets. The report analyzes the markets for various perfusion products across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the perfusion systems market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the perfusion systems market
Table of Contents
Product Code: MD 5190

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
      • 2.2.1.1. Key data from secondary sources
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. Key data from primary sources
      • 2.2.2.2. Key insights from primary sources
      • 2.2.2.3. Key industry insights
  • 2.3. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.4. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. PERFUSION SYSTEMS: MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: PERFUSION SYSTEMS MARKET, BY TYPE (2016)
  • 4.3. CELL PERFUSION SYSTEMS MARKET, BY TYPE, 2016 VS. 2021
  • 4.4. GEOGRAPHIC SNAPSHOT OF THE PERFUSION SYSTEMS MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing prevalence of cardiovascular and respiratory diseases
      • 5.2.1.2. Rising number of organ transplantations
        • 5.2.1.2.1. Growth in aging population, increasing incidence of multiple organ failures
        • 5.2.1.2.2. Government and NGO initiatives to encourage organ donation
      • 5.2.1.3. Increasing investments in cell-based research
      • 5.2.1.4. Increase in biologic manufacturing
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. High cost of organ transplantation
      • 5.2.2.2. Ethical concerns and high cost of cell-based research
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Increasing pharmaceutical research in emerging markets
      • 5.2.3.2. Rising preference for continuous manufacturing
    • 5.2.4. CHALLENGE
      • 5.2.4.1. Organ supply-demand gap

6. CARDIOPULMONARY PERFUSION SYSTEMS MARKET, BY COMPONENT

  • 6.1. INTRODUCTION
  • 6.2. OXYGENATORS
  • 6.3. HEART-LUNG MACHINES
  • 6.4. PERFUSION PUMPS
  • 6.5. CANNULAS
  • 6.6. MONITORING SYSTEMS
  • 6.7. OTHER COMPONENTS
    • 6.7.1. ARTERIAL FILTERS
    • 6.7.2. RESERVOIRS
    • 6.7.3. DATA MANAGEMENT SYSTEMS
    • 6.7.4. CARDIOPLEGIA DELIVERY SYSTEMS
    • 6.7.5. HEAT EXCHANGERS
    • 6.7.6. ACCESSORIES

7. CELL PERFUSION SYSTEMS MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. BIOREACTOR PERFUSION SYSTEMS
  • 7.3. MICROFLUIDIC PERFUSION SYSTEMS
  • 7.4. GRAVITY OR PRESSURE-DRIVEN PERFUSION SYSTEMS
  • 7.5. SMALL-MAMMAL ORGAN PERFUSION SYSTEMS

8. EX VIVO ORGAN PERFUSION MARKET, BY TECHNIQUE

  • 8.1. INTRODUCTION
  • 8.2. HYPOTHERMIC MACHINE PERFUSION
  • 8.3. NORMOTHERMIC MACHINE PERFUSION

9. GLOBAL PERFUSION SYSTEMS MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. U.S.
      • 9.2.1.1. Rise in cardiovascular disease prevalence
      • 9.2.1.2. Technological Advancements in Organ Preservation
      • 9.2.1.3. Increasing Organ Transplants
      • 9.2.1.4. Introduction of the 21st Century Cures Act
      • 9.2.1.5. Favorable Scenario for Cell Research, Growing Research Funding
      • 9.2.1.6. Growth of the Pharmaceutical and Biotechnology Sector
    • 9.2.2. CANADA
      • 9.2.2.1. Increasing incidences of heart diseases
      • 9.2.2.2. Favorable reimbursement scenario for living donors within some provinces
      • 9.2.2.3. Increasing investment in regenerative medicine research projects
  • 9.3. EUROPE
    • 9.3.1. RAPIDLY AGING POPULATION, HIGH PREVALENCE OF CARDIOVASCULAR DISEASES IN EUROPE
    • 9.3.2. EUROPE-5
      • 9.3.2.1. Changes in organ donation laws in Wales
      • 9.3.2.2. Strong academic and research base in Germany
      • 9.3.2.3. Funding for research in the U.K.
      • 9.3.2.4. Increasing cancer research in France
      • 9.3.2.5. Italy: Growing biotech industry to aid market growth
    • 9.3.3. ROE
      • 9.3.3.1. Strong presence of pharmaceutical and biotechnology companies
      • 9.3.3.2. Increasing research in Denmark and Sweden
  • 9.4. ASIA-PACIFIC
    • 9.4.1. INCREASING AGING POPULATION, RISE IN CARDIOVASCULAR SURGERY
    • 9.4.2. JAPAN
      • 9.4.2.1. Rising organ donations and transplants
      • 9.4.2.2. Rise in vaccine production in Japan
      • 9.4.2.3. Regenerative medicine and biomedical & medical research in Japan
    • 9.4.3. CHINA
      • 9.4.3.1. Regulatory framework for voluntary organ donations
      • 9.4.3.2. Increasing government interest in biomedical and biotechnology industries
      • 9.4.3.3. Growth of the pharmaceutical and biotechnology R&D industry and CROs sector
    • 9.4.4. INDIA
      • 9.4.4.1. Religious beliefs and lack of healthcare infrastructure in India
      • 9.4.4.2. Growing pharmaceutical and biotechnology industry, government initiatives
    • 9.4.5. REST OF ASIA-PACIFIC
      • 9.4.5.1. Taiwan: Increasing government support for academic and commercial R&D
      • 9.4.5.2. Establishment of R&D centers in Singapore
      • 9.4.5.3. Korea-U.S. free trade agreement (KORUS)
  • 9.5. REST OF THE WORLD
      • 9.5.1.1. Campaigns to encourage organ donation in Brazil
      • 9.5.1.2. Flourishing biotechnology and pharmaceutical markets in Brazil
      • 9.5.1.3. Significant developments in the pharmaceutical market in Africa
      • 9.5.1.4. Favorable regulatory environment in Saudi Arabia, Iran, and Israel

10. COMPETITIVE LANDSCAPE

  • 10.1. INTRODUCTION
    • 10.1.1. VANGUARDS
    • 10.1.2. INNOVATOR
    • 10.1.3. DYNAMIC
    • 10.1.4. EMERGING
  • 10.2. COMPETITIVE BENCHMARKING
    • 10.2.1. PRODUCT OFFERINGS
    • 10.2.2. BUSINESS STRATEGY

Top 13 companies analyzed for this studies are - Getinge AB (Sweden), Medtronic plc (Ireland), Terumo Corporation (Japan), LivaNova PLC (U.K.), XENIOS AG (Germany), Repligen Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA (Germany), Nipro Corporation (Japan), Harvard Bioscience, Inc. (U.S.), ALA Scientific Instruments, Inc. (U.S.), Lifeline Scientific, Inc. (U.S.), and XVIVO Perfusion AB (Sweden).

11. COMPANY PROFILE (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 11.1. GETINGE AB
  • 11.2. MEDTRONIC PLC
  • 11.3. LIVANOVA PLC
  • 11.4. TERUMO CORPORATION
  • 11.5. NIPRO CORPORATION
  • 11.6. XENIOS AG (ACQUIRED BY FRESENIUS MEDICAL CARE AG & CO. KGAA)
  • 11.7. REPLIGEN CORPORATION
  • 11.8. SPECTRUM LABORATORIES, INC.
  • 11.9. MERCK KGAA
  • 11.10. HARVARD BIOSCIENCE, INC.
  • 11.11. ALA SCIENTIFIC INSTRUMENTS, INC.
  • 11.12. LIFELINE SCIENTIFIC, INC. (ORGAN RECOVERY SYSTEMS, INC.)
  • 11.13. XVIVO PERFUSION AB

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. DISCUSSION GUIDE
  • 12.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
    • 12.3.1. FEATURES AND BENEFITS OF RT:
  • 12.4. AVAILABLE CUSTOMIZATIONS
  • 12.5. RELATED REPORTS
  • 12.6. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: BIOMANUFACTURING PROJECTS ANNOUNCED IN 2015 AND 2016
  • TABLE 2: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
  • TABLE 3: OXYGENATORS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 4: HEART-LUNG MACHINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 5: PERFUSION PUMPS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 6: CANNULAS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 7: MONITORING SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 8: OTHER COMPONENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 10: BIOREACTOR PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 11: MICROFLUIDIC PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 12: GRAVITY OR PRESSURE-DRIVEN PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: SMALL-MAMMAL ORGAN PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 14: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 15: ADVANTAGES AND DISADVANTAGES OF THE HMP TECHNIQUE
  • TABLE 16: HYPOTHERMIC MACHINE PERFUSION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: NORMOTHERMIC MACHINE PERFUSION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 18: GLOBAL PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 19: GLOBAL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 20: NORTH AMERICA: PERFUSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 21: NORTH AMERICA: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 22: NORTH AMERICA: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
  • TABLE 23: NORTH AMERICA: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 24: NORTH AMERICA: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 25: NUMBER OF ORGAN TRANSPLANTS IN THE U.S. (2014-2016)
  • TABLE 26: U.S.: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 27: U.S.: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
  • TABLE 28: U.S.: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 29: U.S.: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 30: CANADA: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 31: CANADA: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
  • TABLE 32: CANADA: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 33: CANADA: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 34: EUROPE: PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 35: EUROPE: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 36: EUROPE: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
  • TABLE 37: EUROPE: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 38: EUROPE: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 39: EUROPE-5: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 40: EUROPE-5: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
  • TABLE 41: EUROPE-5: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 42: EUROPE-5: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 43: INDICATIVE LIST: COMPANIES HEADQUARTERED IN ROE COUNTRIES
  • TABLE 44: ROE: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 45: ROE: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
  • TABLE 46: ROE: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 47: ROE: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 48: ASIA-PACIFIC: PERFUSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 49: ASIA-PACIFIC: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 50: ASIA-PACIFIC: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
  • TABLE 51: ASIA-PACIFIC: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 52: ASIA-PACIFIC: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 53: NUMBER OF ORGAN DONATIONS AND TRANSPLANTS IN JAPAN (2013-2016)
  • TABLE 54: JAPAN: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 55: JAPAN: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
  • TABLE 56: JAPAN: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 57: JAPAN: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 58: CHINA: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 59: CHINA: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
  • TABLE 60: CHINA: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 61: CHINA: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 62: INDIA: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 63: INDIA: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
  • TABLE 64: INDIA: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 65: INDIA: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 66: ROAPAC: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 67: ROAPAC: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
  • TABLE 68: ROAPAC: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 69: ROAPAC: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 70: NUMBER OF ORGAN DONATIONS (2008 VS. 2015)
  • TABLE 71: ROW: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 72: ROW: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
  • TABLE 73: ROW: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 74: ROW: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: PERFUSION SYSTEMS MARKET SEGMENTATION
  • FIGURE 2: PERFUSION SYSTEMS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 3: SAMPLING FRAME: PRIMARY RESEARCH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 6: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 7: RESEARCH DESIGN
  • FIGURE 8: DATA TRIANGULATION METHODOLOGY
  • FIGURE 9: PERFUSION SYSTEMS MARKET, BY TYPE: CARDIOPULMONARY PERFUSION SYSTEMS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 10: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2016 VS. 2021
  • FIGURE 11: EX VIVO ORGAN PERFUSION MARKET SIZE (USD MILLION), BY TECHNIQUE, 2016 VS. 2021
  • FIGURE 12: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2016 VS. 2021
  • FIGURE 13: GEOGRAPHIC SNAPSHOT OF THE PERFUSION SYSTEMS MARKET
  • FIGURE 14: NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE PERFUSION SYSTEMS MARKET IN 2016
  • FIGURE 15: CARDIOPULMONARY PERFUSION SEGMENT DOMINATED THE PERFUSION SYSTEMS MARKET IN 2016
  • FIGURE 16: BIOREACTOR PERFUSION SYSTEMS WILL CONTINUE TO DOMINATE THE CELL PERFUSION SYSTEMS MARKET IN 2021
  • FIGURE 17: NORTH AMERICA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 18: GLOBAL PERFUSION SYSTEMS MARKET SHARE, BY REGION (2016-2021)
  • FIGURE 19: NORTH AMERICA: PERFUSION SYSTEMS MARKET SNAPSHOT
  • FIGURE 20: NIH SPENDING ON STEM CELL RESEARCH, 2013-2016 (USD BILLION)
  • FIGURE 21: NUMBER OF NEW BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2014-2016
  • FIGURE 22: EUROPE: PERFUSION SYSTEMS MARKET SNAPSHOT
  • FIGURE 23: APAC: PERFUSION SYSTEMS MARKET SNAPSHOT
  • FIGURE 24: ROW: PERFUSION SYSTEMS MARKET SNAPSHOT
  • FIGURE 25: DIVE CHART
  • FIGURE 26: GETINGE AB: COMPANY SNAPSHOT (2016)
  • FIGURE 27: GETINGE AB: PRODUCT OFFERING SCORECARD
  • FIGURE 28: GETINGE AB: BUSINESS STRATEGY SCORECARD
  • FIGURE 29: MEDTRONIC PLC: COMPANY SNAPSHOT (2016)
  • FIGURE 30: MEDTRONIC PLC: PRODUCT OFFERING SCORECARD
  • FIGURE 31: MEDTRONIC PLC: BUSINESS STRATEGY SCORECARD
  • FIGURE 32: LIVANOVA PLC: COMPANY SNAPSHOT (2015)
  • FIGURE 33: LIVANOVA PLC: PRODUCT OFFERING SCORECARD
  • FIGURE 34: LIVANOVA PLC: BUSINESS STRATEGY SCORECARD
  • FIGURE 35: TERUMO CORPORATION: COMPANY SNAPSHOT (2015)
  • FIGURE 36: TERUMO CORPORATION: PRODUCT OFFERING SCORECARD
  • FIGURE 37: TERUMO CORPORATION: BUSINESS STRATEGY SCORECARD
  • FIGURE 38: NIPRO CORPORATION: COMPANY SNAPSHOT (2015)
  • FIGURE 39: NIPRO CORPORATION: PRODUCT OFFERING SCORECARD
  • FIGURE 40: NIPRO CORPORATION: BUSINESS STRATEGY SCORECARD
  • FIGURE 41: XENIOS AG: PRODUCT OFFERING SCORECARD
  • FIGURE 42: XENIOS AG: BUSINESS STRATEGY SCORECARD
  • FIGURE 43: REPLIGEN CORPORATION: COMPANY SNAPSHOT (2015)
  • FIGURE 44: REPLIGEN CORPORATION: PRODUCT OFFERING SCORECARD
  • FIGURE 45: REPLIGEN CORPORATION: BUSINESS STRATEGY SCORECARD
  • FIGURE 46: SPECTRUM LABORATORIES, INC.: PRODUCT OFFERING SCORECARD
  • FIGURE 47: SPECTRUM LABORATORIES, INC.: BUSINESS STRATEGY SCORECARD
  • FIGURE 48: MERCK KGAA: COMPANY SNAPSHOT (2015)
  • FIGURE 49: MERCK KGAA: PRODUCT OFFERING SCORECARD
  • FIGURE 50: MERCK KGAA: BUSINESS STRATEGY SCORECARD
  • FIGURE 51: HARVARD BIOSCIENCE, INC.: COMPANY SNAPSHOT (2015)
  • FIGURE 52: HARVARD BIOSCIENCE, INC.: PRODUCT OFFERING SCORECARD
  • FIGURE 53: HARVARD BIOSCIENCE, INC.: BUSINESS STRATEGY SCORECARD
  • FIGURE 54: ALA SCIENTIFIC INSTRUMENTS, INC.: PRODUCT OFFERING SCORECARD
  • FIGURE 55: ALA SCIENTIFIC INSTRUMENTS, INC.: BUSINESS STRATEGY SCORECARD
  • FIGURE 56: LIFELINE SCIENTIFIC, INC.: COMPANY SNAPSHOT (2015)
  • FIGURE 57: LIFELINE SCIENTIFIC, INC.: PRODUCT OFFERING SCORECARD
  • FIGURE 58: LIFELINE SCIENTIFIC, INC.: BUSINESS STRATEGY SCORECARD
  • FIGURE 59: XVIVO PERFUSION AB: COMPANY SNAPSHOT (2015)
  • FIGURE 60: XVIVO PERFUSION AB: PRODUCT OFFERING SCORECARD
  • FIGURE 61: XVIVO PERFUSION AB: BUSINESS STRATEGY SCORECARD
Back to Top